This is a medical procedure where stool, or poop, from a healthy person is transferred into someone else's body. It's done to help treat certain diseases, like severe diarrhea or some types of infections. The goal is to replace the person's gut bacteria with healthy bacteria from the donor.
Every report comes from a Lived member, sent anonymously.
Have you had Fecal Transplant for Pseudomembranous Enterocolitis?
A fecal transplant, or fecal microbiota transplantation (FMT), places stool from a carefully screened healthy donor into the intestine of someone whose own gut bacteria have been badly disrupted. The aim is to restore a diverse community of gut microbes that can keep Clostridioides difficile (C. diff), a bacterium that causes severe and sometimes dangerous diarrhea, from taking hold again. Its main use is preventing C. diff from coming back. The infection usually follows antibiotic treatment, and the antibiotics used to treat it further deplete the gut's protective bacteria, which is one reason it so often recurs. Antibiotics remain the treatment for an active infection; FMT is given after that course to break the cycle. US guidelines say it should be offered after a second recurrence (a third episode), and it may be considered sooner for people at high risk of another recurrence or whose illness was especially severe or hard to treat. In randomized trials of people with recurrent C. diff, donor FMT roughly doubled the chance that the infection resolved compared with antibiotics or placebo. Hospitalized adults with severe C. diff that is not responding to antibiotics are sometimes treated with FMT by colonoscopy as well. FMT now comes in several forms. Conventional FMT uses prepared donor stool delivered by colonoscopy, by enema or, less often, through a tube into the upper intestine. Two products made from screened donor stool and approved by the US Food and Drug Administration (FDA) are also available for adults 18 and older who have finished antibiotics for recurrent C. diff: Rebyota (fecal microbiota, live-jslm), a single dose given into the rectum, and Vowst (fecal microbiota spores, live-brpk), capsules taken by mouth. In their main trials, about 71% of people stayed free of C. diff for eight weeks after Rebyota compared with 58% after placebo, and recurrence within eight weeks was about 12% after Vowst compared with 40% after placebo. The trials enrolled different groups of people, so these numbers cannot be compared directly. Neither product is approved to treat an active infection. FMT is not a general gut-health treatment. Guidelines advise against it for inflammatory bowel disease (Crohn's disease and ulcerative colitis) or irritable bowel syndrome except within clinical trials. They also advise against any fecal microbiota-based therapy for people whose immune systems are severely weakened, while conventional FMT may still be reasonable for some people with milder immune suppression.
Preparation starts with finishing the antibiotic course for the current C. diff episode, usually vancomycin or fidaxomicin, two antibiotics that act on C. diff in the gut. The antibiotic is then stopped shortly before the transplant so it does not kill the incoming donor bacteria. The gap depends on the form: conventional FMT is commonly given within about two days of the last dose, Rebyota 24 to 72 hours afterward, and Vowst 2 to 4 days afterward. For conventional FMT, the donor is either an anonymous donor from a stool bank or, at some centers, someone the patient knows. Either way, the donor completes a detailed health questionnaire and blood and stool tests for transmissible infections, including drug-resistant bacteria. The rest of the preparation depends on the route. Delivery by colonoscopy requires the same bowel preparation as a standard colonoscopy: usually a clear-liquid diet for about a day and a laxative solution to empty the colon. Because sedation affects judgment and memory for the rest of the day, you will need someone to take you home. Enema delivery generally needs no bowel preparation, although you may be asked to empty your bladder and bowel beforehand. Some centers give a medicine that slows the bowel so the donor material stays in longer. Before Vowst, you drink a laxative (10 ounces of magnesium citrate) the day before and then have nothing but small sips of water for at least 8 hours before the first dose; people with kidney problems may be given a different laxative. Tell the care team about all your medicines, especially any that suppress the immune system, and about any serious food allergies, since products made from stool may contain traces of food allergens. Ask exactly when to take your last antibiotic dose, because timing varies between centers and products.
What the treatment feels like depends on how the donor material is delivered. By colonoscopy, you receive sedation through an IV (a small tube placed in a vein), so most people are asleep or very drowsy and feel little. The doctor passes a thin, flexible camera through the rectum and releases the donor stool suspension, usually high in the colon so it can spread through the whole large intestine. The procedure usually takes 30 to 60 minutes. By enema, including Rebyota, no sedation is needed. You lie on your left side or in a knee-chest position while a lubricated tube is placed a few inches into the rectum, and the liquid flows in by gravity over a few minutes. You then stay lying down and hold it in for as long as instructed, often 15 to 30 minutes or more, to keep the material in place. Vowst involves no procedure. After the laxative and fast, you swallow four capsules on an empty stomach before breakfast once a day for three days, usually at home. Less often, donor material is delivered into the upper intestine through a thin tube passed through the nose or during an upper endoscopy. People treated this way are kept sitting upright for several hours afterward to lower the chance of inhaling material if they vomit.
Most people go home the same day. Mild bloating, gas, cramping, loose stools or constipation are common in the first few days, and some people have chills or a low fever; these usually settle within a day or two. In the Vowst trial, bloating, tiredness, constipation and chills were the most common effects. The main thing to watch over the following weeks is whether the C. diff diarrhea returns, and follow-up usually continues for at least eight weeks. If diarrhea comes back, meaning three or more loose stools in 24 hours for two days in a row, contact your care team. It may need testing and further treatment, and a repeat transplant is sometimes an option. Antibiotics disrupt gut bacteria and are the main trigger for C. diff, so avoid antibiotics you do not truly need and tell any clinician who prescribes one about your C. diff history. Rebyota labeling advises against oral antibiotics for up to eight weeks afterward unless your doctor directs otherwise, and Vowst is not taken at the same time as antibiotics. Probiotics are not recommended to prevent recurrence; a varied diet with plenty of fiber-rich fruits and vegetables is encouraged instead. Careful handwashing and cleaning bathroom surfaces at home help prevent reinfection from lingering C. diff spores. After delivery by colonoscopy, seek medical care right away for severe belly pain, a high fever or one that does not settle, bloody stools that do not improve, rectal bleeding that will not stop, dizziness or weakness, because these can signal bleeding or a tear in the bowel wall.
For C. diff, FMT has a good short-term safety record. In randomized trials, serious problems were no more common than with antibiotic treatment alone, although the trials were too small to settle the question for rare events. Most side effects are the temporary digestive symptoms described above. The most important specific risk is passing an infection from donor to recipient. Screening and testing are designed to prevent this, but the risk cannot be eliminated. In 2019 the FDA reported that two immunocompromised adults developed serious infections with drug-resistant E. coli traced to donor stool that had not been tested for it, and one of them died; the FDA then required donor screening specifically for drug-resistant bacteria. This risk is a main reason guidelines advise against these therapies for people with severely weakened immune systems. The delivery method adds its own risks. Colonoscopy carries small risks of bleeding, a tear in the colon wall that may need surgery, and reactions to sedation such as breathing problems or low blood pressure; inhaling stomach contents during sedation has been reported. Serious problems appear more common when material is delivered into the upper intestine, including pneumonia from inhaled material after vomiting. Enemas and capsules avoid sedation and these procedural risks. Long-term effects are not well understood. Long-term follow-up data are limited, and researchers have raised the theoretical possibility that donor microbes could influence other aspects of health years later. FMT also does not always work: some people have another recurrence and need further treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Fecal Transplant, what to expect, or ask the community a question.